Zomedica Corp. is an animal health company focused on creating and marketing diagnostic and therapeutic products for companion animals, including dogs, cats, and horses. The company addresses unmet needs of clinical veterinarians by providing innovative technologies that improve patient care and enhance the economic health of veterinary practices. Its product portfolio emphasizes point-of-care diagnostics and therapeutic devices designed to streamline workflows, increase practice profitability, and improve outcomes for pets and their owners.
Zomedica generates revenue primarily through the sale of its diagnostic and therapeutic medical devices to veterinarians and veterinary practices. Key revenue drivers include the TRUFORMA® diagnostic platform, TRUVIEW® digital microscopy system, VETGuardian® vital signs monitoring system, PulseVet® shockwave therapy devices, Assisi Loop® tPEMF™ products, and VETIGEL® hemostatic gel. The company sells these products directly to veterinary professionals, through online orders, and via third-party distributors such as MWI Animal Health, Covetrus, Patterson Veterinary, Amazon, and Chewy. Revenue has grown from $0 in 2020 to $32.0 million in 2025, reflecting expanding product adoption and commercialization efforts.
The company operates through the following segments: Diagnostic Products and Therapeutic Device Products.
- Diagnostic Products: This segment includes the TRUFORMA® Bulk Acoustic Wave (BAW) point-of-care diagnostic platform, which offers assays for feline optimized TSH, canine endogenous ACTH, canine Free T4, canine and feline cobalamin and folate, equine endogenous ACTH, canine NT-proBNP, canine progesterone, equine insulin, equine cortisol, canine TSH, canine cortisol, canine pancreatic lipase, canine and feline total T4, and equine progesterone. The TRUFORMA® system delivers results within 25 minutes using patented BAW technology. The segment also includes the TRUVIEW® digital microscopy platform, launched in mid-2023, which provides automated slide preparation and remote interpretation by board-certified pathologists within two hours, with AI-enhanced capabilities added in January 2026 for automated hematology blood film analysis. Additionally, the VETGuardian® Zero Touch vital signs remote monitoring system enables contact-free, continuous monitoring of pets' temperature, pulse, and respiration using patented doppler technology, with real-time notifications and smart device access for veterinarians; the VETGuardian PLUS™ version launched in December 2025 improved ease of use and workflow efficiency.
- Therapeutic Device Products: This segment features the PulseVet® electrohydraulic shockwave therapy platform, which uses sound waves to treat musculoskeletal conditions in horses and small animals, including tendon and ligament injuries, osteoarthritis, and difficult-to-heal wounds, with the X-Trode® handpiece enabling small animal use without sedation. The Assisi Loop® line of products delivers targeted pulsed electromagnetic field (tPEMF™) focused energy to treat pain and inflammation, with variations including the Assisi Loop Lounge®, Assisi EquiLoop™, DentaLoop®, and Assisi Calmer Canine® devices for separation anxiety in dogs. VETIGEL® hemostatic gel, launched in January 2025 under license from Cresilon, Inc., is a fast-acting, prescription gel that stops bleeding in seconds via mechanical action without applied pressure, forming a strong mechanical barrier upon contact with blood and allowing natural fibrin patch formation. All therapeutic products are distributed through traditional animal health distributors, online retailers, and the company’s own website.
Zomedica operates in a competitive animal health diagnostics and therapeutics market, facing established players such as Idexx Laboratories, Inc., Antech Diagnostics, Heska Corporation, Zoetis Inc., and Bionote USA Inc. in diagnostics, and Companion Animal Health, K-Laser, Summus Medical Laser, and ELvation Medical GmbH in shockwave therapy. The company differentiates itself through its focus on point-of-care innovations, rapid product development cycles, and lower regulatory barriers compared to human medical devices, allowing faster commercialization. Its competitive advantages include a growing intellectual property portfolio with 57 issued U. S. patents and 100 international patents, strategic acquisitions that expanded manufacturing and R&D capabilities, and a veterinarian-centric business model designed to improve practice economics and workflow efficiency.
Zomedica serves veterinarians and veterinary practices across the United States and internationally, with customers including small animal, equine, and mixed-practice clinics. The company distributes its products through veterinary distributors such as MWI Animal Health (a division of Cencora), Covetrus, Patterson Veterinary, and others, as well as through online retail channels including Amazon and Chewy. Internationally, it markets its Assisi and PulseVet product lines through in-country distributors in Europe, Asia, Australia/New Zealand, and South America, leveraging its global subsidiary and distribution channels to expand market reach.